A.V. Sultanbaev1,2, K.V. Men’shikov1,2, Sh.I. Musin1,2, A.A. Izmaylov1,2, E.V. Popova1, N.I. Sultanbaeva1, I.A. Menshikova2
1Republican Clinical Oncology Dispensary, Ufa
2Bashkir State Medical University, Ufa
Sultanbaev Aleksandr V. ― Cand. of Sci. (Med.), Head of the Department of antitumor drug Therapy of the Republican Clinical Oncology Dispensary
73/1 Oktyabrya Ave., Ufa, 450054, Russian Federation, e-mail: firstname.lastname@example.org, ORCID ID: 0000-0003-0996-5995
Abstract. Most patients with metastatic urothelial cancer receive chemotherapy, which most often allows for an objective response, but at the same time the tumor progresses quite quickly. With the progression of the disease, the only treatment option remains the re-appointment of antitumor drug therapy, which negatively affects the quality of life and does not allow achieving sufficiently long-term control over the tumor. Currently, the first-line therapy of metastatic urothelial carcinoma remains unchanged and is based on combinations with platinum-containing therapy. One of the promising areas of treatment of common solid tumors is supportive therapy. The results of the JAVELIN Blade 100 study indicate the possibility of prolonging disease control after effective first-line platinum-containing chemotherapy and increasing the overall survival rate(s). This publication analyzes a case of treatment with the checkpoint inhibitor avelumab in a patient with metastatic urothelial cancer. Immunotherapy with avelumab as support for the 1st line of platinum-containing chemotherapy allowed to achieve control over the tumor in the form of stabilization of the disease during 8 months of therapy, which persists to the present. As a result of treatment with avelumab, an undesirable phenomenon was registered in the patient in the form of hypothyroidism of the first stage, which is controlled by concomitant hormone therapy.
Key words: bladder cancer, tumor control, avelumab, anti-PD L1 therapy, urothelial cancer.